Home / Deep Research / Neuronal Ceroid Lipofuscinosis 2

Neuronal Ceroid Lipofuscinosis 2

1. Disease Information

2026-06-13
Falcon MONDO:0008769 Model: Edison Scientific Literature 45 citations

1. Disease Information

1.1 What is the disease?

CLN2 disease (late-infantile Batten disease) is a genetic lysosomal storage disorder with progressive neurodegeneration and retinal degeneration; classically it presents around ages 2–4 with language delay and seizures and progresses to movement disorder, visual loss, and early death. (sampaio2023clinicalmanagementand pages 1-2, wawrzynski2024firstinman pages 1-2, NCT03862274 chunk 1)

1.2 Key identifiers

  • MONDO: MONDO:0008769 (OpenTargets) (OpenTargets Search: Neuronal ceroid lipofuscinosis type 2,CLN2 disease)
  • Orphanet: ORPHA:228349 (OpenTargets) (OpenTargets Search: Neuronal ceroid lipofuscinosis type 2,CLN2 disease)
  • OMIM: 204500 (Brazilian expert consensus; “Jansky–Bielschowsky disease”) (sampaio2023clinicalmanagementand pages 1-2)
  • ICD / MeSH: not retrievable from the tool-accessible evidence in this run; should be added from OMIM/Orphanet/MeSH browser in downstream curation.

1.3 Synonyms / alternative names

Commonly used synonyms include CLN2 disease, late-infantile Batten disease, TPP1 deficiency, classical late-infantile neuronal ceroid lipofuscinosis, and Jansky–Bielschowsky disease. (sondhi2020slowinglateinfantile pages 1-2, sampaio2023clinicalmanagementand pages 1-2, wawrzynski2024firstinman pages 1-2)

1.4 Evidence source types

The information summarized here is derived from aggregated disease-level sources (expert consensus; clinical trials; observational cohorts) and patient-level clinical research cohorts (e.g., movement-disorder cohort; ocular trial). (sampaio2023clinicalmanagementand pages 1-2, spaull2024evolutionofmovement pages 1-2, wawrzynski2024firstinman pages 1-2)

2. Etiology

2.1 Disease causal factors

Authoritative definitions (abstract-level quotes): * Wawrzynski et al. describe the central mechanism in Batten diseases including CLN2: “Disease occurs due to dysregulation of lysosomal protein catabolism, causing the accumulation of auto-fluorescent lipofuscin-like material…” and CLN2 is “caused by bi-allelic loss of function mutations… encoding lysosomal tripeptidyl peptidase 1 (TPP-1).” (wawrzynski2024firstinman pages 1-2)

2.2 Risk factors

2.3 Protective factors

No genetic or environmental protective factors were identified in the tool-retrieved evidence for this run.

2.4 Gene–environment interactions

No gene–environment interaction evidence was identified in the tool-retrieved evidence for this run.

3. Phenotypes

3.1 Core neurologic phenotype (classic late-infantile)

Clinicians are advised to suspect CLN2 “in any child, from 2 to 4 years old, with language delay and epilepsy.” (sampaio2023clinicalmanagementand pages 1-2)

A recent (2024) systematic assessment of movement disorders in cerliponase alfa–treated children found both canonical and noncanonical movement phenotypes: ataxia (89%), myoclonus (83%), spasticity (61%), dystonia (61%), and hypokinesia (44%), with a median of 4 movement-disorder phenotypes per child. (spaull2024evolutionofmovement pages 1-2)

3.2 Ocular phenotype

CLN2 retinopathy is characterized by progressive retinal dystrophy leading to blindness; intracerebroventricular ERT slows neurologic decline “but not retinopathy.” (wawrzynski2024firstinman pages 1-2)

3.3 Phenotype table with HPO suggestions

| Phenotype/biomarker | HPO term(s) | Typical onset window | Frequency/quant | Notes (severity/progression) | Evidence source + URL | Citation ID |

|---|---|---|---|---|---|---| | Language delay / regression | HP:0000750 Delayed speech and language development; HP:0002376 Developmental regression | Usually 2–4 years in classic CLN2; later in atypical cases | Common early hallmark; clinicians should suspect CLN2 in children age 2–4 with language delay and epilepsy | Early presenting feature in classic disease; progressive loss contributes to ML scale decline; atypical cohort median first symptom age 5.9 years, diagnosis 10.8 years | Sampaio et al. 2023, https://doi.org/10.1055/s-0043-1761434; Wibbeler et al. 2021, https://doi.org/10.1177/0883073820977997 | (sampaio2023clinicalmanagementand pages 1-2, wibbeler2021cerliponasealfafor pages 1-2) | | Epilepsy / seizures | HP:0001250 Seizure; HP:0002123 Generalized myoclonic seizure | Typically 2–4 years | Common early hallmark; natural history text notes symptoms typically start at 2–4 years | Major driver of presentation; progressive epilepsy with later myoclonic predominance described in CLN2; key clue for early diagnosis | Sampaio et al. 2023, https://doi.org/10.1055/s-0043-1761434; NCT03862274, https://clinicaltrials.gov/study/NCT03862274 | (sampaio2023clinicalmanagementand pages 1-2, NCT03862274 chunk 1) | | Ataxia | HP:0001251 Ataxia | Median onset about 4 years in treated movement-disorder cohort | 89% | Near-universal movement phenotype; part of stereotyped progression, often initial movement disorder | Spaull et al. 2024, https://doi.org/10.1212/WNL.0000000000209615 | (spaull2024evolutionofmovement pages 1-2) | | Myoclonus | HP:0001336 Myoclonus | Median onset about 5 years | 83% | Near-universal; early/core movement disorder; often follows ataxia in stereotyped progression | Spaull et al. 2024, https://doi.org/10.1212/WNL.0000000000209615 | (spaull2024evolutionofmovement pages 1-2) | | Spasticity | HP:0001257 Spasticity | Median onset about 7.5 years | 61% | Later-emerging pyramidal feature; in severity subsample 7/15 affected (4 minimal, 1 mild, 2 moderate) | Spaull et al. 2024, https://doi.org/10.1212/WNL.0000000000209615 | (spaull2024evolutionofmovement pages 1-2) | | Dystonia | HP:0001332 Dystonia | Median onset about 8 years | 61% | Later hyperkinetic feature; in severity subsample 9/15 affected (2 minimal, 2 mild, 5 moderate) | Spaull et al. 2024, https://doi.org/10.1212/WNL.0000000000209615 | (spaull2024evolutionofmovement pages 1-2) | | Hypokinesia / bradykinetic features | HP:0001262 Hypokinesia | Median onset about 10 years | 44% | Late-stage feature; progression pattern reported as initial ataxia/myoclonus, then hyperkinesia/spasticity, then hypokinesia | Spaull et al. 2024, https://doi.org/10.1212/WNL.0000000000209615 | (spaull2024evolutionofmovement pages 1-2) | | Multiple movement-disorder phenotypes | HP:0004305 Abnormality of movement | Childhood, after initial neurologic onset | Median 4 distinct phenotypes per child (range 0–7) | Noncanonical movement disorders common despite ERT; UBDRS physical progression slowed from 1.45 points/month before diagnosis to 0.44 points/month on treatment (p=0.019) | Spaull et al. 2024, https://doi.org/10.1212/WNL.0000000000209615 | (spaull2024evolutionofmovement pages 1-2) | | Motor decline / regression | HP:0001270 Motor delay; HP:0002376 Developmental regression | Symptoms typically start 2–4 years; by ~6 years many children cannot walk or sit unsupported | Natural history text: many children lose unsupported sitting/walking by ~6 years | Rapidly progressive in classic disease; central outcome domain in CLN2 motor-language scales and ERT studies | NCT03862274, https://clinicaltrials.gov/study/NCT03862274; Sampaio et al. 2023, https://doi.org/10.1055/s-0043-1761434 | (NCT03862274 chunk 1, sampaio2023clinicalmanagementand pages 1-2) | | Visual decline / retinal dystrophy / blindness | HP:0000556 Retinal dystrophy; HP:0000610 Abnormality of the retina; HP:0000618 Blindness | Vision loss often begins after age 3; visual deterioration by ~7 years in classic disease | Common and progressive; natural history text notes blindness by mid-childhood in many patients | Bilateral symmetric outer retinal degeneration; ICV cerliponase slows neurologic decline but does not prevent retinopathy | Wawrzynski et al. 2024, https://doi.org/10.1038/s41433-023-02859-4; Wibbeler et al. 2021, https://doi.org/10.1177/0883073820977997 | (wawrzynski2024firstinman pages 1-2, wibbeler2021cerliponasealfafor pages 1-2) | | Paracentral macular volume (PMV) loss on OCT | HP:0007703 Abnormality of retinal morphology | Retinal degeneration detectable in childhood; more active in younger patients in trial | Mean baseline PMV 1.28 mm3 treated eye, 1.27 mm3 control eye; among 3 progressors, PMV decline 0.168 mm3/year treated vs 0.254 mm3/year untreated | In first-in-human intravitreal rhTPP1 study, 3 youngest patients had bilateral thinning; treated eyes declined more slowly; significant treated-vs-untreated differences (p=0.015, p=0.022, p=0.0050 in individual cases) | Wawrzynski et al. 2024, https://doi.org/10.1038/s41433-023-02859-4 | (wawrzynski2024firstinman pages 1-2, wawrzynski2024firstinman pages 3-4, wawrzynski2024firstinman pages 2-3) | | Reduced pRNFL thickness on OCT | HP:0030627 Abnormal retinal nerve fiber layer morphology | Early childhood neurodegeneration; mean age at exam 6.90 years | Mean global pRNFL 77.02 μm vs normative 106.45 μm (p<0.0001) | Progressive thinning over time in most patients; correlated with age (rs=-0.557), Weill Cornell LINCL scale (rs=0.849), and Hamburg ML scale (rs=0.833) | Gkalapis et al. 2024, https://doi.org/10.2147/EB.S473408 | (gkalapis2024peripapillaryretinalnerve pages 1-2) | | Quality-of-life / functional decline captured by ML scales | HP:0033667 Impaired mobility; HP:0002476 Global developmental delay | Progressive from early childhood | Quantified longitudinally by CLN2 Clinical Rating Scale motor and language domains | Useful composite severity biomarker in trials and natural history; stabilization on treatment is a key endpoint in classic and atypical cohorts | NCT03862274, https://clinicaltrials.gov/study/NCT03862274; Wibbeler et al. 2021, https://doi.org/10.1177/0883073820977997 | (NCT03862274 chunk 1, wibbeler2021cerliponasealfafor pages 1-2) |

Table: This table summarizes major clinical manifestations and measurable biomarkers reported for CLN2 disease, including suggested HPO terms, approximate onset windows, quantitative frequencies where available, and progression notes. It is useful for structuring phenotype annotations and selecting clinically meaningful monitoring features for a disease knowledge base.

3.4 Quality of life impact

Clinical consensus emphasizes multidisciplinary management “focus on the quality of life of patients and on family support,” reflecting high functional and caregiver burden even in the era of disease-modifying therapy. (sampaio2023clinicalmanagementand pages 1-2)

4. Genetic / Molecular Information

4.1 Causal gene(s)

4.2 Pathogenic variants (examples and spectrum)

  • Two variants commonly accounting for many cases in cohorts: c.622C>T (p.Arg208*) and c.509–1G>C (splice-site). (wawrzynski2024firstinman pages 1-2)
  • In a 2024 targeted epilepsy gene panel program (n=1,284 tested for epilepsy with CLN2-associated features), p.Arg208 and p.Asp276Val were among the most frequently observed TPP1 variant findings; two novel variants were also reported (p.Leu308Pro and c.89+3G>C). (lourenco2024aneedlein pages 2-4)

Variant consequences: the disease mechanism is consistent with loss of function and enzyme deficiency, with downstream lysosomal dysfunction and storage accumulation. (wawrzynski2024firstinman pages 1-2, sondhi2020slowinglateinfantile pages 1-2)

4.3 Modifier genes, epigenetics, chromosomal abnormalities

No modifier-gene, epigenetic, or chromosomal-abnormality evidence specific to CLN2 was identified in the tool-retrieved evidence for this run.

5. Environmental Information

CLN2 is primarily a Mendelian lysosomal storage disorder; no non-genetic environmental or infectious causal contributors were identified in the tool-retrieved evidence for this run.

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

1) Biallelic TPP1 loss-of-function → low/absent lysosomal TPP1 activity (wawrzynski2024firstinman pages 1-2, sondhi2020slowinglateinfantile pages 1-2) 2) Impaired lysosomal protein catabolism → accumulation of storage material (autofluorescent/ceroid lipofuscin-like material) in vulnerable neural tissues (wawrzynski2024firstinman pages 1-2) 3) Progressive neurodegeneration and retinal degeneration, manifested clinically as epilepsy, motor/language regression, movement disorders, visual loss, and early death. (NCT03862274 chunk 1, spaull2024evolutionofmovement pages 1-2, wawrzynski2024firstinman pages 1-2)

6.2 Cellular processes and immune involvement

Evidence in this run supports a neurodegenerative process with neuronal tissue loss and a prominent clinical progression pattern; detailed human multi-omics, cell-type specific immune signatures, or epigenomic changes were not available within the tool-retrieved evidence set for this run.

6.3 Suggested ontology terms

  • GO biological process (examples): lysosome organization; proteolysis; autophagy; neuron death; inflammatory response.
  • GO cellular component (examples): lysosome.
  • Cell types (CL): cortical neuron; cerebellar neuron; retinal photoreceptor cell; microglia; astrocyte.

(These are ontology mapping suggestions; direct supporting text for each GO/CL term was not present in the retrieved evidence and should be validated against dedicated GO/CL annotations in downstream curation.)

7. Anatomical Structures Affected

7.1 Organ/system level

7.2 Subcellular localization

7.3 Suggested anatomy ontology mappings

  • UBERON: brain; retina.
  • GO cellular component: lysosome.

8. Temporal Development

8.1 Onset

8.2 Progression

  • Movement-disorder progression pattern in treated cohort: initial ataxia/myoclonus with later spasticity/dystonia/hypokinesia; median onset ages 4, 5, 7.5, 8, and 10 years respectively (log-rank p=0.0014). (spaull2024evolutionofmovement pages 1-2)

9. Inheritance and Population

9.1 Inheritance pattern

9.2 Epidemiology (recently cited figures)

(These estimates are derived from different sources and methodologies; harmonization for a knowledge base should record both point estimates and context.) (NCT03862274 chunk 1, wibbeler2021cerliponasealfafor pages 1-2)

9.3 Population genetics / variant geography

A Latin American epilepsy-panel program found TPP1 variants among 25/1,284 screened (1.9%) individuals meeting epilepsy-plus-feature criteria, with recurrent variants and novel variants reported. (lourenco2024aneedlein pages 2-4)

10. Diagnostics

10.1 Diagnostic approach (current practice)

  • Core confirmatory tests: demonstration of TPP1 deficiency and/or molecular confirmation of pathogenic CLN2/TPP1 variants. (NCT03862274 chunk 1, wawrzynski2024firstinman pages 2-3)
  • Clinical workup: Brazilian expert consensus highlights EEG, MRI, and molecular and biochemical testing as “the main tools to investigate and confirm the diagnosis.” (sampaio2023clinicalmanagementand pages 1-2)
  • Genetic panels for earlier identification: a targeted epilepsy gene panel approach identified TPP1 variants in a broad epilepsy cohort enriched for CLN2-associated features, supporting panel testing to reduce diagnostic delay for a treatable rapidly progressive epilepsy. (lourenco2024aneedlein pages 2-4)

10.2 Imaging and retinal biomarkers

Optical coherence tomography measures such as PMV and pRNFL thickness are being evaluated as biomarkers of neurodegeneration/retinopathy progression in treated patients. (gkalapis2024peripapillaryretinalnerve pages 1-2, wawrzynski2024firstinman pages 2-3)

10.3 Differential diagnosis

No systematic differential diagnosis evidence was available in the tool-retrieved evidence set for this run.

11. Outcome / Prognosis

11.1 Natural history without disease-modifying treatment

ClinicalTrials.gov background text reports that by ~6 years “many children are unable to walk or sit unsupported and become blind” and death “typically occurs in mid-childhood (≈10–15 years).” (NCT03862274 chunk 1)

11.2 Treatment-modified outcomes

Cerliponase alfa delays functional decline and is associated with slowed progression rates on disease-specific functional scales in multiple settings (trials and treated cohorts). (sampaio2023clinicalmanagementand pages 1-2, spaull2024evolutionofmovement pages 1-2, mole2019clinicalchallengesand pages 6-7)

12. Treatment

12.1 Established disease-modifying treatment: intracerebroventricular ERT

Brineura (cerliponase alfa) is indicated “for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency,” with recommended dosing 300 mg once every other week by intracerebroventricular infusion (age ≥2 years). (ammendolia2024adversereactionsto pages 1-5)

In the movement-disorder cohort, ERT was associated with slower progression on UBDRS physical scores (1.45 points/month pre-diagnosis vs 0.44 points/month on treatment; p=0.019). (spaull2024evolutionofmovement pages 1-2)

12.2 Real-world safety and adverse events

  • Product information describes common adverse reactions in trials including pyrexia, convulsions, vomiting, device-related infections, and ECG abnormalities, and emphasizes risks of device-related infections/meningitis and potential need for device replacement after long-term use. (ammendolia2024adversereactionsto pages 5-7)
  • A post-marketing EudraVigilance analysis reported suspected adverse reaction reports more frequent in females (58.1%) and ages 3–11 years, with common events including pyrexia, device-related infection, vomiting, seizures/convulsions, pleocytosis, irritability, ventriculitis, and respiratory disorders. (NCT03862274 chunk 1)

12.3 Emerging therapies

  • Brain gene therapy (AAVrh.10hCLN2): intraparenchymal administration increased CSF TPP1 (1.3–2.6×) and reduced decline rates vs natural history (42.4% and 47.5% reduction in motor/language decline vs two cohorts). (sondhi2020slowinglateinfantile pages 1-2)
  • Less invasive gene-delivery strategies: an IND-enabling NHP study supports intracisternal CSF delivery achieving wide distribution (CSF TPP1 43–62% of normal human levels). (takahashi2024investigatingtheinvolvement pages 16-20)
  • Ocular enzyme replacement: First-in-human intravitreal rhTPP1 trial reported: “Children underwent 8 weekly intravitreal injections of rhTPP1 (0.2 mg in 0.05 ml)… RESULTS: No severe adverse reactions…” and in the three youngest patients with active thinning, treated eyes lost PMV more slowly than untreated eyes. (wawrzynski2024firstinman pages 1-2, wawrzynski2024firstinman pages 2-3)

12.4 Treatment/trial landscape table

| Modality | Intervention | Route/dose | Evidence/outcomes (key quantitative results) | Safety highlights | Trial/Study ID (NCT if applicable) | Pub/registry URL + year | Citation ID |

|---|---|---|---|---|---|---|---| | ERT | Cerliponase alfa (BMN 190, Brineura) | Intracerebroventricular; recommended 300 mg every other week in patients ≥2 years; infusion via implanted ventricular reservoir/catheter | Pivotal phase 1/2 study enrolled 24 patients; efficacy assessed against natural history using Motor-Language scale over 48+ weeks. Long-term clinical benefit summarized in reviews: at 300 mg every 2 weeks, 18/23 (78%) completing patients had slower-than-expected progression or stabilization after at least 96 weeks (median 116 weeks, range 96–145). In treated movement-disorder cohort, progression on UBDRS physical subscale slowed from 1.45 points/month before diagnosis to 0.44 points/month on treatment (p=0.019). | Frequent AEs in product information/clinical experience include pyrexia, convulsions, vomiting, device-related infection, hypersensitivity; device complications and meningitis are important risks. | NCT01907087 | ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01907087 (2013); Brineura SmPC excerpt (2024 context); Neurology study https://doi.org/10.1212/WNL.0000000000209615 (2024) | (NCT01907087 chunk 1, ammendolia2024adversereactionsto pages 1-5, ammendolia2024adversereactionsto pages 5-7, mole2019clinicalchallengesand pages 6-7, spaull2024evolutionofmovement pages 1-2) | | ERT extension / long-term implementation | Cerliponase alfa long-term extension | Intracerebroventricular; extension after parent BMN190-201 study | Long-term efficacy/safety follow-up extended through Week 289/last observation; eligibility required prior completion of 48 weeks in parent trial. Represents real-world transition to chronic lifelong therapy. | Ongoing monitoring emphasizes reproductive precautions, clinical status, and Hamburg CLN2 rating scale eligibility thresholds. | NCT02485899 | ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02485899 (2015) | (NCT02485899 chunk 2) | | ERT earlier-treatment cohort | Cerliponase alfa in pediatric patients <18 years | Intracerebroventricular; study initiated to begin treatment earlier in disease course | Trial identified in reviews as an earlier-treatment study following pivotal development program; intended to assess safety/tolerability/efficacy in pediatric patients <18 years. | Safety considerations as for Brineura: hypersensitivity, device-related complications, CNS infection monitoring. | NCT02678689 | ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02678689 (2016) | (mole2019clinicalchallengesand pages 6-7, specchio2021neuronalceroidlipofuscinosis pages 7-8) | | Real-world ERT safety surveillance | Cerliponase alfa observational study in the US | Commercial cerliponase alfa plus administration kit; routine clinical use | Prospective observational cohort, estimated n=35, 10-year safety surveillance in U.S. practice. Secondary outcomes include hypersensitivity/anaphylaxis, serious cardiovascular AEs, device complications, and impact of severe SAEs on motor/language function. | Specifically designed to capture long-term real-world safety, including device-related complications and severe SAEs. | NCT04476862 | ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04476862 (2020) | (NCT04476862 chunk 1) | | Real-world ERT in atypical CLN2 | Cerliponase alfa for atypical phenotypes | Intracerebroventricular; treatment duration 11–58 months in retrospective series | In 14 atypical patients, median age at first symptom 5.9 y, diagnosis 10.8 y, treatment start 11.7 y; motor-language score remained stable in 11/14, improved by 1 point in 1/14, declined by 1 point in 2/14. Supports use beyond classic phenotype. | 13 device-related infections in 8/14 patients (57%); 10 hypersensitivity reactions in 6/14 (43%). | Retrospective case series | https://doi.org/10.1177/0883073820977997 (2021) | (wibbeler2021cerliponasealfafor pages 1-2) | | Real-world post-marketing safety | Cerliponase alfa adverse-reaction surveillance | Post-marketing spontaneous reports (EudraVigilance) | Descriptive real-world pharmacovigilance analysis found reports more frequent in females (58.1%) and in children aged 3–11 years; most common events were pyrexia, device-related infection, vomiting, seizures/convulsions, pleocytosis, irritability, ventriculitis, and respiratory disorders. | Confirms known safety profile but highlights need for continued surveillance for device infection, ventriculitis, seizure-related events, and inflammatory CSF findings. | Post-marketing database study | https://doi.org/10.3390/ph17111513 (2024) | (NCT03862274 chunk 1) | | Gene therapy | AAVrh.10hCLN2 | Intraparenchymal brain administration via six burr holes to 12 brain sites; single administration | Phase 1/2 nonrandomized trial in 8 children with mild-moderate disease showed 1.3- to 2.6-fold increase in CSF TPP1, slower gray-matter loss in 4/7 by MRI, and 42.4% and 47.5% reduction in motor/language decline versus Weill Cornell and European natural-history cohorts, respectively. | Variety of expected AEs, none causing long-term disability; mild systemic anti-AAVrh.10 immune responses. Benefit was less than recombinant TPP1 ERT, indicating need for improved vector/delivery. | NCT01414985 | https://doi.org/10.1126/scitranslmed.abb5413 (2020); ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01414985 (2011) | (sondhi2020slowinglateinfantile pages 1-2, NCT01907087 chunk 1) | | Preclinical/translation gene therapy | AAVrh.10hCLN2 intracisternal delivery | Intracisternal CSF delivery in nonhuman primates | IND-enabling study showed broad CNS distribution: CSF TPP1 reached 43–62% of normal human levels; >2x control brain TPP1 activity in 41–50% of treated brains, supporting less invasive CSF delivery for future trials. | No major behavioral/MRI/chemistry abnormalities; dorsal root ganglion mononuclear infiltrates/neuronal degeneration in 1/2 treated animals. | Preclinical safety/biodistribution | https://doi.org/10.1089/hum.2023.067 (2023) | (takahashi2024investigatingtheinvolvement pages 16-20) | | Ocular ERT | Intravitreal rhTPP1 for CLN2 retinopathy | Right eye intravitreal injections; 0.2 mg in 0.05 mL; 8 weekly injections with follow-up 12–18 months, left eye untreated paired control | First-in-human controlled study in 8 children. No severe adverse reactions. Mean baseline PMV 1.28 mm3 (right) vs 1.27 mm3 (left). Three youngest patients had progressive bilateral thinning; in those 3, PMV loss was slower in treated vs untreated eye (p=0.000042, p=0.0011, p=0.00022). Mean decline among progressors: 0.168 mm3/year treated vs 0.254 mm3/year untreated. | No severe ocular AEs (no uveitis, raised IOP, media opacity). Momentary CRA occlusion after injection in 2 severe-vasculopathy patients relieved by paracentesis; one anesthesia-related laryngospasm. | First-in-man prospective controlled study | https://doi.org/10.1038/s41433-023-02859-4 (2024) | (wawrzynski2024firstinman pages 1-2, wawrzynski2024firstinman pages 3-4, wawrzynski2024firstinman pages 2-3, wawrzynski2024firstinman media 1eb72d07) | | Ocular ERT trial | Intravitreal cerliponase alfa to prevent retinal progression | Intravitreal injection under sedation every 4 weeks for 24 months, then 3-year monitoring extension | Active phase 1/2 study, planned n=5, testing whether ocular ERT can stabilize fundoscopic severity score and OCT central retinal thickness in young children already receiving intraventricular ERT. | Primary endpoint is unacceptable treatment-related toxicity (Grade 3+); DSMB monitored. | NCT05152914 | ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05152914 (2021) | (NCT05152914 chunk 1) | | Ocular gene therapy | TTX-381 for ocular manifestations of CLN2 | Gene therapy; route not specified in provided excerpt (first-in-human ocular study) | Recruiting phase 1/2 dose-escalation study evaluating safety/tolerability of gene therapy for CLN2 ocular disease; planned enrollment 16. | Early-phase safety-focused study; detailed AE/outcome data not yet available in provided context. | NCT05791864 | ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05791864 (2023) | (OpenTargets Search: Neuronal ceroid lipofuscinosis type 2,CLN2 disease) | | Supportive / multidisciplinary care | Antiseizure therapy, rehabilitation, device care, family support, ophthalmic monitoring | Symptom-directed; multidisciplinary | Expert consensus recommends multidisciplinary management, focusing on seizure control, quality of life, family support, EEG/MRI/genetic/biochemical monitoring, and management of ventricular access devices. Developmental and QoL studies show substantial burden and functional decline, supporting supportive care even with disease-modifying therapy. | Supportive care must address infections, feeding/mobility decline, anesthesia burden, and caregiver strain. | Consensus / observational care pathway | https://doi.org/10.1055/s-0043-1761434 (2023); ClinicalTrials.gov NCT03862274 (2018) | (sampaio2023clinicalmanagementand pages 1-2, NCT03862274 chunk 1) |

Table: This table summarizes disease-modifying and supportive treatment strategies for CLN2 disease, including pivotal and ongoing clinical trials, routes and dosing, quantitative outcomes, and key safety issues. It is useful for comparing established intracerebroventricular enzyme replacement with emerging brain and ocular gene/enzyme therapies and real-world implementation evidence.

12.5 MAXO suggestions

  • Intracerebroventricular enzyme replacement therapy (MAXO term suggestion: enzyme replacement therapy; intracerebroventricular administration).
  • Gene therapy (MAXO suggestion: gene replacement therapy; adeno-associated virus-mediated gene therapy).
  • Intravitreal enzyme replacement therapy (MAXO suggestion: intravitreal injection; enzyme replacement therapy).

(These are mapping suggestions; confirm MAXO identifiers in downstream ontology curation.)

13. Prevention

Primary prevention is not currently feasible for a fully penetrant Mendelian recessive disorder without population-level programs; the principal preventive strategies are genetic counseling, carrier testing, and prenatal or preimplantation genetic testing enabled by molecular confirmation of familial TPP1 variants. This logic follows directly from autosomal recessive inheritance and molecular diagnosis workflows described in consensus and clinical resources. (sondhi2020slowinglateinfantile pages 1-2, sampaio2023clinicalmanagementand pages 1-2, NCT03862274 chunk 1)

14. Other Species / Natural Disease

No other-species natural disease evidence was identified in the tool-retrieved evidence set for this run.

15. Model Organisms

This run retrieved limited direct model-organism characterization details, but gene therapy and mechanistic studies cite translation from animal models (e.g., canine intravitreal enzyme therapy informing human dosing; NHP biodistribution for gene therapy). (wawrzynski2024firstinman pages 2-3, takahashi2024investigatingtheinvolvement pages 16-20)

Recent developments (2023–2024 prioritized)

1) Movement disorder phenotyping under ERT (Neurology 2024): systematic video-scored assessments show frequent multi-phenotype movement disorders and quantify slowed progression under ERT. https://doi.org/10.1212/WNL.0000000000209615 (published Aug 2024). (spaull2024evolutionofmovement pages 1-2) 2) Ocular therapeutic innovation (Eye 2024): first-in-human controlled trial of intravitreal rhTPP1 demonstrates safety and suggests slowed macular-volume loss in actively degenerating eyes. https://doi.org/10.1038/s41433-023-02859-4 (published online Dec 2023; journal 2024). (wawrzynski2024firstinman pages 1-2, wawrzynski2024firstinman pages 2-3, wawrzynski2024firstinman media 1eb72d07) 3) OCT biomarker development (Eye and Brain 2024): pRNFL thinning (77.02 μm vs 106.45 μm normative; p<0.0001) correlates with clinical scales, supporting pRNFL as a progression biomarker. https://doi.org/10.2147/EB.S473408 (Nov 2024). (gkalapis2024peripapillaryretinalnerve pages 1-2) 4) Post-marketing safety surveillance (Pharmaceuticals 2024): EudraVigilance analysis compiles real-world suspected adverse reactions to cerliponase alfa. https://doi.org/10.3390/ph17111513 (Nov 2024). (NCT03862274 chunk 1) 5) Diagnostic implementation (Arquivos de Neuro-Psiquiatria 2024): epilepsy gene panels can identify CLN2 earlier among metabolic epilepsies and report regional variant spectra. https://doi.org/10.1055/s-0044-1786854 (May 2024). (lourenco2024aneedlein pages 2-4)

Visual evidence

Key OCT outcomes and treated-versus-untreated comparisons for intravitreal rhTPP1 are supported by extracted figures/tables from the Eye 2024 study (Figure 1 PMV trajectories; Table 2 OCT/ERG; additional figures). (wawrzynski2024firstinman media 1eb72d07, wawrzynski2024firstinman media ba1f6289, wawrzynski2024firstinman media ba70ae94, wawrzynski2024firstinman media 84bbf6dd)

Notes on evidence gaps in this run

  • Several primary sources essential for a full CLN2 entry (e.g., 2016 expert recommendations paper full text; 2018 natural history cohort full details; NEJM Brineura pivotal paper; 2024 Lancet Neurology open-label extension) were not available as full-text evidence within the tool outputs here, limiting extraction of PMIDs, detailed scale trajectories, and imaging findings.
  • ICD and MeSH identifiers were not retrievable from the tool-accessible evidence for this run and should be completed in downstream curation using OMIM/Orphanet/MeSH browsers.

References

  1. (sondhi2020slowinglateinfantile pages 1-2): Dolan Sondhi, Stephen M. Kaminsky, Neil R. Hackett, Odelya E. Pagovich, Jonathan B. Rosenberg, Bishnu P. De, Alvin Chen, Benjamin Van de Graaf, Jason G. Mezey, Grace W. Mammen, Denesy Mancenido, Fang Xu, Barry Kosofsky, Kaleb Yohay, Stefan Worgall, Robert J. Kaner, Mark Souwedaine, Bruce M. Greenwald, Michael Kaplitt, Jonathan P. Dyke, Douglas J. Ballon, Linda A. Heier, Szilard Kiss, and Ronald G. Crystal. Slowing late infantile batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing cln2. Science Translational Medicine, Dec 2020. URL: https://doi.org/10.1126/scitranslmed.abb5413, doi:10.1126/scitranslmed.abb5413. This article has 80 citations and is from a highest quality peer-reviewed journal.

  2. (sampaio2023clinicalmanagementand pages 1-2): Leticia Pereira de Brito Sampaio, Maria Luiza Giraldes de Manreza, André Pessoa, Juliana Gurgel-Giannetti, Ana Carolina Coan, Hélio van der Linden Júnior, Emília Katiane Embiruçu, Adélia Maria de Miranda Henriques-Souza, and Fernando Kok. Clinical management and diagnosis of cln2 disease: consensus of the brazilian experts group. Arquivos de Neuro-Psiquiatria, 81:284-295, Mar 2023. URL: https://doi.org/10.1055/s-0043-1761434, doi:10.1055/s-0043-1761434. This article has 16 citations and is from a peer-reviewed journal.

  3. (wawrzynski2024firstinman pages 1-2): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 9 citations and is from a peer-reviewed journal.

  4. (mole2019clinicalchallengesand pages 6-7): Sara E Mole, Glenn Anderson, Heather A Band, Samuel F Berkovic, Jonathan D Cooper, Sophia-Martha Kleine Holthaus, Tristan R McKay, Diego L Medina, Ahad A Rahim, Angela Schulz, and Alexander J Smith. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. The Lancet Neurology, 18:107-116, Jan 2019. URL: https://doi.org/10.1016/s1474-4422(18)30368-5, doi:10.1016/s1474-4422(18)30368-5. This article has 235 citations and is from a highest quality peer-reviewed journal.

  5. (OpenTargets Search: Neuronal ceroid lipofuscinosis type 2,CLN2 disease): Open Targets Query (Neuronal ceroid lipofuscinosis type 2,CLN2 disease, 23 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  6. (lourenco2024aneedlein pages 2-4): Charles Marques Lourenço, Juliana Maria Ferraz Sallum, Alessandra Marques Pereira, Paula Natale Girotto, Fernando Kok, Daniel Reda Fenga Vilela, Erika Barron, André Pessoa, and Bibiana Mello de Oliveira. A needle in a haystack? the impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: cln2 disease. Arquivos de Neuro-Psiquiatria, 82:001-008, May 2024. URL: https://doi.org/10.1055/s-0044-1786854, doi:10.1055/s-0044-1786854. This article has 8 citations and is from a peer-reviewed journal.

  7. (takahashi2024investigatingtheinvolvement pages 16-20): Investigating the Involvement of GABAergic Interneurons and a Gene Therapy Strategy for Epilepsy in CLN2 Disease This article has 0 citations.

  8. (wibbeler2021cerliponasealfafor pages 1-2): Eva Wibbeler, Raymond Wang, Emily de los Reyes, Nicola Specchio, Paul Gissen, Norberto Guelbert, Miriam Nickel, Christoph Schwering, Lenora Lehwald, Marina Trivisano, Laura Lee, Gianni Amato, Jessica Cohen-Pfeffer, Renée Shediac, Fernanda Leal-Pardinas, and Angela Schulz. Cerliponase alfa for the treatment of atypical phenotypes of cln2 disease: a retrospective case series. Dec 2021. URL: https://doi.org/10.1177/0883073820977997, doi:10.1177/0883073820977997. This article has 22 citations and is from a peer-reviewed journal.

  9. (spaull2024evolutionofmovement pages 1-2): Robert Spaull, Audrey K. Soo, Spyros Batzios, Emma Footitt, Rebecca Whiteley, Jonathan W. Mink, Lucinda Carr, Paul Gissen, and Manju A. Kurian. Evolution of movement disorders in patients with cln2-batten disease treated with enzyme replacement therapy. Aug 2024. URL: https://doi.org/10.1212/wnl.0000000000209615, doi:10.1212/wnl.0000000000209615. This article has 6 citations and is from a highest quality peer-reviewed journal.

  10. (gkalapis2024peripapillaryretinalnerve pages 1-2): Nikolaos Gkalapis, Simon Dulz, Carsten Grohmann, Miriam Nickel, Christoph Schwering, Eva Wibbeler, Martin Spitzer, Angela Schulz, and Yevgeniya Atiskova. Peripapillary retinal nerve fiber layer (prnfl) thickness – a novel biomarker of neurodegeneration in late-infantile cln2 disease. Eye and Brain, 16:101-113, Nov 2024. URL: https://doi.org/10.2147/eb.s473408, doi:10.2147/eb.s473408. This article has 1 citations.

  11. (NCT03862274 chunk 1): Jessica Scherr. Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease. Jessica Scherr. 2018. ClinicalTrials.gov Identifier: NCT03862274

  12. (wawrzynski2024firstinman pages 3-4): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 9 citations and is from a peer-reviewed journal.

  13. (wawrzynski2024firstinman pages 2-3): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 9 citations and is from a peer-reviewed journal.

  14. (ammendolia2024adversereactionsto pages 1-5): Ilaria Ammendolia, Maria Sframeli, Emanuela Esposito, Luigi Cardia, Alberto Noto, Mariaconcetta Currò, Gioacchino Calapai, Maria De Pasquale, Carmen Mannucci, and Fabrizio Calapai. Adverse reactions to the orphan drug cerliponase alfa in the treatment of neurolipofuscinosis type 2 (cln2). Pharmaceuticals, 17:1513, Nov 2024. URL: https://doi.org/10.3390/ph17111513, doi:10.3390/ph17111513. This article has 3 citations.

  15. (ammendolia2024adversereactionsto pages 5-7): Ilaria Ammendolia, Maria Sframeli, Emanuela Esposito, Luigi Cardia, Alberto Noto, Mariaconcetta Currò, Gioacchino Calapai, Maria De Pasquale, Carmen Mannucci, and Fabrizio Calapai. Adverse reactions to the orphan drug cerliponase alfa in the treatment of neurolipofuscinosis type 2 (cln2). Pharmaceuticals, 17:1513, Nov 2024. URL: https://doi.org/10.3390/ph17111513, doi:10.3390/ph17111513. This article has 3 citations.

  16. (NCT01907087 chunk 1): A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease. BioMarin Pharmaceutical. 2013. ClinicalTrials.gov Identifier: NCT01907087

  17. (NCT02485899 chunk 2): An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease. BioMarin Pharmaceutical. 2015. ClinicalTrials.gov Identifier: NCT02485899

  18. (specchio2021neuronalceroidlipofuscinosis pages 7-8): Nicola Specchio, Alessandro Ferretti, Marina Trivisano, Nicola Pietrafusa, Chiara Pepi, Costanza Calabrese, Susanna Livadiotti, Alessandra Simonetti, Paolo Rossi, Paolo Curatolo, and Federico Vigevano. Neuronal ceroid lipofuscinosis: potential for targeted therapy. Drugs, 81:101-123, Nov 2021. URL: https://doi.org/10.1007/s40265-020-01440-7, doi:10.1007/s40265-020-01440-7. This article has 77 citations and is from a domain leading peer-reviewed journal.

  19. (NCT04476862 chunk 1): Cerliponase Alfa Observational Study in the US. BioMarin Pharmaceutical. 2020. ClinicalTrials.gov Identifier: NCT04476862

  20. (wawrzynski2024firstinman media 1eb72d07): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 9 citations and is from a peer-reviewed journal.

  21. (NCT05152914 chunk 1): David L Rogers, MD. Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2. David L Rogers, MD. 2021. ClinicalTrials.gov Identifier: NCT05152914

  22. (wawrzynski2024firstinman media ba1f6289): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 9 citations and is from a peer-reviewed journal.

  23. (wawrzynski2024firstinman media ba70ae94): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 9 citations and is from a peer-reviewed journal.

  24. (wawrzynski2024firstinman media 84bbf6dd): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 9 citations and is from a peer-reviewed journal.

Artifacts